In clinical cohorts of ER+ breast cancer patients, PDCD4 expression is strongly linked to patient outcomes, as demonstrated by patients with low PDCD4 expression levels having poor disease-free survival and increased tumor grade. This evidence concerns the gene ESR1 and breast cancer.